...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts >Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
【24h】

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

机译：复发和难治多骨髓瘤的当前和新的治疗策略：更新

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new options are currently available for the treatment of relapsed multiple myeloma, including recently approved drugs, such as the second- and third-generation proteasome inhibitors carfilzomib and ixazomib, the immunomodulatory agent pomalidomide, the monoclonal antibodies daratumumab and elotuzumab and the histone deacetylase inhibitor panobinostat, but also new targeted agents are under active investigation (e.g. signal transduction modulators, kinesin spindle protein inhibitors, and inhibitors of NF-kB, MAPK, AKT). We here describe a new paradigm for the treatment of relapsed multiple myeloma. The final goal should be finding a balance among efficacy, toxicity, and cost and, at the end of the road, achieving long-lasting control of the disease and eventually even cure in a subset of patients.
机译：虽然近年来，多发性骨髓瘤患者的存活至少翻了一番，但大多数患者最终复发，并且在这个阶段的治疗可能是特别复杂的。在复发时，将替代药物用于预期给出的那些是目前的实践。然而，许多新选择目前可用于治疗复发的多发性骨髓瘤，包括最近批准的药物，例如第二代蛋白酶体抑制剂Carfilzomib和Ixazomib，免疫调节剂氯脲胺，单克隆抗体达拉穆巴布和Elotuzumab和组蛋白和组蛋白Deacetylase抑制剂Panobinostat，但也是新的靶向剂在积极调查（例如信号转导调节剂，Kinesin主轴蛋白抑制剂和NF-KB，MAPK，AKT的抑制剂）。我们在这里描述了一种用于治疗复发多发性骨髓瘤的新范式。最终目标应在疗效，毒性和成本以及在道路尽头进行余额，实现对疾病的长期控制，最终甚至在患者的子集中治愈。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号